01.07.2016 12:24:20

OraSure, AbbVie Announce Early Termination Of HCV Co-Promotion Agreement

(RTTNews) - OraSure Technologies (OSUR) announced OraSure Technologies and AbbVie have mutually agreed to an early termination of their Master Program Services and Co-Promotion Agreement under which the companies have been co-promoting OraSure's OraQuick HCV Rapid Antibody Test in the U.S.

The agreement was originally scheduled to continue through December 31, 2019 and will now end on December 31, 2016. Following the termination of the agreement, AbbVie will be relieved of its co-promotion obligations, including its obligation to detail the OraQuick HCV Rapid Test into physician offices, and will have no further financial obligations to OraSure.

Analysen zu AbbVie Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

AbbVie Inc 188,74 -0,17% AbbVie Inc
OraSure Technologies Inc. 3,74 -0,53% OraSure Technologies Inc.